SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: MulhollandDrive who wrote (515)8/19/1997 2:11:00 PM
From: David Bogdanoff   of 2173
 
BOP:
>>Do you think after listening to
Haugen that they will remedy the the protocol problem with the next trials?<<

Well, I'll put it this way; if they do remedy the problem, it will be due more to luck than anything else. Its difficult to correct a protocol after the study has started. There are a number of inherent difficulties with these studies and an unusually good understanding of
clinical trials is required. This sub-optimal performance is not uncommon for small biotechs with little in-house experience, and there is are pressures to take short-cuts to speed product to market. It is something to keep in mind when looking at other companies in the diabetes market.

David

ps: lest it seem totally negative, remember that J&J is still behind this program and that company must see something there.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News